Antibody Response to Influenza Vaccination in Renal Transplant Patients

摘要: Thirty renal transplant recipients received 0.5 ml of Influenza Virus Vaccine, Bivalent, USP, intramuscularly. Serum hemagglutination-inhibiting and nasal secretory neutralizing antibodies were measured before 3 to 4 weeks after vaccination. Creatinine clearance urinary protein excretion weekly for 8 Ten 13 patients (77%) with creatinine greater than or equal 70 ml/min-1.73m2 (group I) had a fourfold increase in antibody titers influenza A B virus vaccination, while only six 17 (35%) II) similar (chi-square = 5.129; P less 0.05). Six (46%) group I whereas none II 7.135; 0.01). There no adverse effects on the allografts. Only minor side noted few patients. Because its safety antigenicity, vaccination should be offered particularly during threats epidemic outbreaks.